Question

英语高手 求助汉翻译英。 快。50分+20分=70分。要准确度。

目前进入中国的外商制药企业已有1500家，世界前20位的跨国制药企业都已在我国合资办厂，有的还开办了独资企业，进口药、合资药的市场份额已超过了50%，这是造成看病贵的重要原因之一。
外资企业的药，即使过了专利期、在中国生产出来的品种，中国企业生产的同品种的价格也只是外资企业药品价格的40.13%，有的甚至只是外资企业的10%左右。而本次针对“单独定价”产品进行的调整，有望进一步摆正中外药企博弈的天平。
未来继续分期分批降价
不过，上述国内厂家的观点，在外资企业方面并没有得到认同。
昨日，中国外商投资企业协会药品研制和开发行业委员会（RDPAC）一位高管在接受本报采访时表示，与国际对比，我国仿制药出厂价格为国际总体价格水平的22%~30%，以其价格为基准来调整原研药价格将抑制行业质量体系投入，不利于我国医药市场和制药产业的健康发展。
对于跨国制药企业来说，由于其研发一款新药的投入基本在10亿美元以上，如此巨大的投入需要高额的药费来给予回报。
以下前二位都是机器翻译，要英语高手翻译，要准确度。谢谢

Answer 1

At present,the foreign pharmaceutical enterprise Currently which entered in China has 1,500, the world's top 20 multinational pharmaceutical enterprises have engaged in our joint venture, some also opened solely invested enterprise,the share of market of import medicine, joint venture medicine has more than 50%, this is one of the important reasons which it's too wxpensive to see a doctor.
Foreign capital enterprise's medicine, even exceed the patent period, the medicine price which Chinese enterprises manufactured with the same varieties is 41.3% than foreign capital enterprise's price, some even just about 10% of a foreign-capital enterprise's. And this is aimed at "separate pricing" product adjustment,it is expected to further adjust chinese-foreign medicine enterprises' balance.
Depreciating group after group at different times in future.
But the above domestic manufacturer's views are not approved by foreign-capital enterprise.
Yesterday, a executives of China Association of Enterprises with Foreign Investment (CAEFI) drug research and development industry committee (RDPAC) indicate that Compared with international,our copy drug price is 22%~30% of international general price leve, which based on the original drug price adjustment would restain industry quality system input, against our country medicine market and the healthy development of the pharmaceutical industry.
For multinational pharmaceutical enterprise,due to a new drug of its r&d input is more than $1 billion basically, such a great investment need great number of expenses for medicine to give in return.

手工翻译，供参考！

Answer 2

Currently entering the Chinese foreign pharmaceutical enterprise has 1,500 home, the world's top 20 multinational pharmaceutical enterprises have engaged in our joint venture, some still opened solely invested enterprise, JinKouYao, joint venture medicine market share has more than 50%, this is causing a doctor expensive one of the important reasons.
Foreign capital enterprise medicine, even after a patent period, produced in China, Chinese enterprises manufacturing varieties with varieties of foreign capital enterprise price also just the price of drugs 40.13%, some even just about 10% of a foreign-capital enterprise. And this is aimed at "separate pricing" product adjustment, is expected to further adjust chinese-foreign medicine enterprises game balance.
Further price. Installment partial
But the domestic manufacturer views in a foreign-capital enterprise, not the approval.
Yesterday, China association of enterprises with foreign investment drug research and development industry committee (RDPAC listings) a executives in accepting our newspaper, said in an interview with the international comparison, producer prices in China for international generic-drug 22% of the general price level, with its ~ 30% price as a benchmark to adjust branded drug prices will restrain industry quality system input, against our country medicine market and the healthy development of the pharmaceutical industry.
For multinational pharmaceutical enterprise that, of a new drug because of its r&d input of more than $10 billion in basically, such a great investment need high expenses for medicine to give in return.

追问

一看 就是机器翻译。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。为什么要浪费这时间？

Answer 3

At present,the foreign pharmaceutical enterprise Currently which entered in China has 1,500, the world's top 20 multinational pharmaceutical enterprises have engaged in our joint venture, some also opened solely invested enterprise,the share of market of import medicine, joint venture medicine has more than 50%, this is one of the important reasons which it's too wxpensive to see a doctor.
Foreign capital enterprise's medicine, even exceed the patent period, the medicine price which Chinese enterprises manufactured with the same varieties is 41.3% than foreign capital enterprise's price, some even just about 10% of a foreign-capital enterprise's. And this is aimed at "separate pricing" product adjustment,it is expected to further adjust chinese-foreign medicine enterprises' balance.
Depreciating group after group at different times in future.
But the above domestic manufacturer's views are not approved by foreign-capital enterprise.
Yesterday, a executives of China Association of Enterprises with Foreign Investment (CAEFI) drug research and development industry committee (RDPAC) indicate that Compared with international,our copy drug price is 22%~30% of international general price leve, which based on the original drug price adjustment would restain industry quality system input, against our country medicine market and the healthy development of the pharmaceutical industry.
For multinational pharmaceutical enterprise,due to a new drug of its r&d input is more than $1 billion basically, such a great investment need great number of expenses for medicine to give in return,

Answer 4

To date, 1500 foreign pharmaceutical companies have entered China. The world's top 20 largest international pharmaceutical companies have already set up factories jointly with Chinese partners, and some of them have even established wholly owned subsidiaries. As a result, the amount of imported medicines and those produced by foreign-invested companies have accounted for more than a half of the drug market, which is a main contributor for the high cost of medical treatment.

Medicines produced by foreign companies, even off-patent ones, are sold at much higher prices than those produced by Chinese companies, while the pricing for the latter only accounts for 40.13% or, even as low as 10% of the former. The restructuring of medical pricing this time, focused on the products with "self-directed" prices, is supposed to rebalance a level playing field for both Chinese and foreign enterprises in the pharmaceutical industry.

Price will be cut step by step in batches in the coming period

The opinions from the domestic companies mentioned above have not been confirmed by their foreign-invested counterparts, though.

Compared with the global market, the exworks prices for Chinese generic medicines are 22%-30% of the overall international price level. It will constrain investment in the industrial quality system if we set the prevailing global prices as standards for regulating the price of indigenously-developed medicines, leading to some harmful effects to our domestic medical market and the sound development of our own pharmaceutical industry. For international pharmaceutical companies, the R&D investment for a new drug could easily exceed 1 billion dollars, a huge input that needs high price in return, said one senior executive from the R&D-based Pharmaceutical Association Committee of the China Association of Enterprises with Foreign Investment during the interview by our newspaper yesterday.